Orfan N, Patterson R, Dykewicz M S
Department of Medicine, Northwestern University Medical School, Chicago, ILL 60611-3008.
JAMA. 1990 Sep 12;264(10):1287-9.
Angiotensin converting enzyme (ACE) inhibitors have been associated with the onset of angioedema in a small subset of treated patients. The angioedema commonly involves the face and oropharyngeal tissues and may result in life-threatening airway compromise. The mechanism by which ACE inhibitors precipitate angioedema has not been well-defined, and retrospective analysis of reported cases has failed to identify a group of patients at high risk. We report four cases of ACE inhibitor-related angioedema that required immediate medical intervention. All four cases occurred in patients with a prior history of idiopathic angioedema, an otherwise uncommon clinical entity. These observations suggest that patients with a history of idiopathic angioedema are at increased risk for the development of ACE inhibitor-related angioedema and should be treated cautiously with this class of drugs.
血管紧张素转换酶(ACE)抑制剂与一小部分接受治疗的患者发生血管性水肿有关。血管性水肿通常累及面部和口咽组织,可能导致危及生命的气道梗阻。ACE抑制剂引发血管性水肿的机制尚未明确,对报告病例的回顾性分析未能确定一组高危患者。我们报告4例需要立即进行医学干预的与ACE抑制剂相关的血管性水肿病例。所有4例均发生在有特发性血管性水肿既往史的患者中,特发性血管性水肿是一种临床少见的疾病。这些观察结果表明,有特发性血管性水肿病史的患者发生与ACE抑制剂相关的血管性水肿的风险增加,使用这类药物时应谨慎治疗。